B+
Bull case
25%
Probability
Target price
$5.75
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
CTKB
Cytek BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 showed 6% revenue growth, stronger instrument demand in the U.S. and China, recurring revenue at 35% of trailing revenue, 142 quarterly instrument additions, and a $1 million increase in the 2026 revenue-guidance midpoint [#SEC-8K-2026-08-05].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Analyst coverage and peer comparability are limited, and no verified post-earnings target or estimate revisions are available.
Momentum
94
Value
41
Sentiment
37
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.75 · Bull $5.75 · Bear $3.25Analysis 2026-08-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $5.75
Why
Momentum94 · Δ7d -1.0
Value41 · Δ7d -0.1
Sentiment37 · Δ7d -4.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Analyst coverage and peer comparability are limited, and no verified post-earnings target or estimate revisions are available.
- • Net loss and adjusted EBITDA deteriorated year over year despite revenue growth [#SEC-8K-2026-08-05].
- • Profitability remains weak: net loss widened year over year, adjusted EBITDA turned negative, operating expenses rose materially, and the reported gross-margin improvement was partly affected by a one-time tariff refund [#SEC-8K-2026-08-05].
Catalyst clock
2026-08-05
Mixed Q2 2026 earnings follow-up
Lead driver: Value · See fundamentals
Momentum
94
8% active weight
Current posture
7d trendFlat
Δ7d
-1.0
Δ21d
-1.8
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
37
45% active weight
Current posture
7d trendSoftening
Δ7d
-4.7
Δ21d
-1.3
Why this grade
Composite grade D. Momentum 93.7 / Value 40.6 / Sentiment 36.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$4.75
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.25
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$726.61M
Beta
1.30
Shares Out
129.98M
P/E (TTM) · Derived
-10.7
P/S (TTM)
3.38
P/FCF (TTM)
53.79
Rev YoY
+5.6%
EPS YoY
+113.4%
Gross Margin
+53.2%
Op Margin
-21.6%
Net Debt
-$228.51M
Current Ratio
4.48
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data